Reported Saturday, Daiichi Sankyo And Merck's Ifinatamab Deruxtecan Shows Response Rates In Extensive-Stage Small Cell Lung Cancer In Phase 2 IDeate-Lung01 Trial
Portfolio Pulse from Benzinga Newsdesk
Daiichi Sankyo and Merck's drug, ifinatamab deruxtecan, shows a 54.8% response rate in a Phase 2 trial for small cell lung cancer, with 12 mg/kg chosen as the optimal dose for further studies.
September 09, 2024 | 8:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Daiichi Sankyo's ifinatamab deruxtecan shows a 54.8% response rate in a Phase 2 trial for small cell lung cancer, with 12 mg/kg chosen as the optimal dose for further studies.
The positive trial results for ifinatamab deruxtecan could boost investor confidence in Daiichi Sankyo's oncology pipeline, potentially leading to a short-term stock price increase.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Merck's collaboration with Daiichi Sankyo on ifinatamab deruxtecan shows a 54.8% response rate in a Phase 2 trial for small cell lung cancer, with 12 mg/kg chosen as the optimal dose for further studies.
Merck's involvement in the successful trial of ifinatamab deruxtecan may enhance its reputation in oncology, potentially leading to a positive short-term impact on its stock price.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70